Phase II study of maytansine in advanced breast cancer
Edmonson, J.H.; Rubin, J.; Kvols, L.K.; O'Connell, M.J.; Frytak, S.; Green, S.J.
Cancer Treatment Reports 65(5-6): 536-537
1981
ISSN/ISBN: 0361-5960 PMID: 7237478 Document Number: 170895
Document emailed within 1 workday
Related Documents
Edmonson, J.H.; Hahn, R.G.; Creagan, E.T.; O'Connell, M.J. 1983: Phase II study of maytansine in advanced sarcomas Cancer Treatment Reports 67(4): 401-402Rosenthal, S.; Harris, D.T.; Horton, J.; Glick, J.H. 1980: Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 64(10-11): 1115-1117
Tominaga, T.; Nomura, Y.; Adachi, I.; Aoyama, H.; Nagao, K.; Mitsuyama, S.; Nakamura, Y.; Ogita, M.; Sano, M.; Takashima, S. 1994: Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 809-816
Rouësse, J.G.; Le Chevalier, T.; Caille, P.; Mondesir, J.M.; Sancho-Garnier, H.; May-Levin, F.; Spielmann, M.; De Jager, R.; Amiel, J.L. 1985: Phase Ii study of elliptinium in advanced breast cancer Cancer Treatment Reports 69(6): 707-708
Ogawa, M.; Kubo, K.; Tominaga, T.; Nomura, Y.; Ota, K.; Yoshida, M.; Taguchi, T.; Hoshino, A. 1986: Phase Ii study of mitoxantrone in advanced breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(5): 1980-1984
Lionetto, R.; Pronzato, P.; Conte, P.F.; Sertoli, M.R.; Amoroso, D.; Rosso, R. 1986: Idarubicin in advanced breast cancer: a phase II study Cancer Treatment Reports 70(12): 1439-1440
Yap, H.Y.; Salem, P.; Hortobagyi, G.N.; Bodey, G.P.; Buzdar, A.U.; Tashima, C.K.; Blumenschein, G.R. 1978: Phase Ii study of cis-dichlorodiammineplatinum(II) in advanced breast cancer Cancer Treatment Reports 62(3): 405-408
Amadori, D.; Frassineti, G.L.; Zoli, W.; Tienghi, A.; Ravaioli, A.; Casadei Giunchi, D.; Gentile, A.; Salzano, E. 1996: A Phase I/Ii study of paclitaxel and doxorubicin in the treatment of advanced breast cancer Seminars in Oncology 23(1 Suppl 1: 19-23
Wada, Y.; Otoshi, M.; Jitsuko, A.; Nishikawa, H.; Takahara, S.; Tsubono, M.; Imai, S. 2007: A phase Ii study of weekly paclitaxel for advanced or recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1041-1045
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
Dieras, V.; Marty, M.; Tubiana, N.; Corette, L.; Morvan, F.; Serin, D.; Mignot, L.; Chazard, M.; Garet, F.; Onetto, N. 1995: Phase Ii randomized study of paclitaxel versus mitomycin in advanced breast cancer Seminars in Oncology 22(4 Suppl 8: 33-39
Pedrazzoli, P.; Zamagni, C.; Martoni, A.; Capotorto, A.M.; Da Prada, G.A.; Pavesi, L.; Preti, P.; Lelli, G.; Pannuti, F.; Robustelli della Cuna, G. 1994: Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study Tumori 80(4): 273-275
Taguchi, T.; Mori, S.; Abe, R.; Hasegawa, K.; Morishita, Y.; Tabei, T.; Sasaki, Y.; Fujita, M.; Enomoto, K.; Hamano, K. 1994: Late phase Ii clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(15): 2625-2632
Ithimakin, S.; Ratanawichitrasin, A.; Veerasarn, V.; Akewanlop, C.; Soparattanapaisarn, N.; Rojananin, S.; O-Charoenrat, P.; Prasarttong-Osoth, P.; Srimuninnimit, V. 2013: A phase Ii study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer Journal of the Medical Association of Thailand 96(Suppl 2): S67-S74
Lehnert, M.; Biffl, G.; Wascher, H.; Jordis-Lohausen, K.; Wählby, S. 1986: A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase Ii study Seminars in Oncology 13(1 Suppl 1: 32-34
Nichols, W.C.; Kvols, L.K.; Ingle, J.N.; Edmonson, J.H.; Ahmann, D.L.; Rubin, J.; O'Connell, M.J. 1978: Phase Ii study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy Cancer Treatment Reports 62(5): 837-839
Cosmas, C.; Tsavaris, N.; Malamos, N.; Tsakonas, G.; Gassiamis, A.; Skopelitis, H.; Soukouli, G.; Polyzos, A.; Mylonakis, N.; Karabelis, A. 2005: Dose escalation of docetaxel and ifosfamide in patients with advanced breast cancer failing prior anthracyclines: mature results of a phase I-Ii study Journal of Buon: Official Journal of the Balkan Union of Oncology 10(3): 337-346
Eagan, R.T.; Creagan, E.T.; Ingle, J.N.; Frytak, S.; Rubin, J. 1978: Phase II evaluation of maytansine in patients with metastatic lung cancer Cancer Treatment Reports 62(10): 1577-1579
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508
Chahinian, A.P.; Nogeire, C.; Ohnuma, T.; Greenberg, M.L.; Sivak, M.; Jaffrey, I.S.; Holland, J.F. 1979: Phase I study of weekly maytansine given by iv bolus or 24-hour infusion Cancer Treatment Reports 63(11-12): 1953-1960